Deep Brain Stimulation for Parkinson’s Disease: The CNS Releases New Guidelines
Schaumburg, Illinois, April 23, 2018 – The Congress of Neurological Surgeons (CNS) recently released a new clinical practice guideline on deep brain stimulation for treatment of patients with Parkinson’s disease: Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients with Parkinson’s Disease. The guideline has been published in full text on the CNS website and as an executive summary in Neurosurgery.
Parkinson’s disease is characterized by a variety of symptoms that present in a variety of combinations and severities, and can have varied responses to both medications and deep brain stimulation. This new guideline addresses seven clinical questions and provides guidance on the selection of stimulation targets.
The efficacy of bilateral deep brain stimulation for the treatment of motor symptoms and levodopa-induced dyskinesias in Parkinson’s disease patients is well established. However, the effectiveness of selecting different stimulation targets is less clear. To date, two main targets have been proposed for the treatment of motor symptoms of Parkinson’s disease: the subthalamic nucleus (STN) and globus pallidus internus (GPi). While there is evidence to suggest that both are effective when combined with best medical treatment versus best medical treatment alone, the circumstances in which one target should be selected over the other are still disputed.
A multidisciplinary task force of clinical experts systematically reviewed and analyzed the literature, and produced seven recommendations on the use of STN and GPi deep brain stimulation in patients with Parkinson’s disease.
According to Clement Hamani, MD, chair of the deep brain stimulation for Parkinson’s disease guidelines panel, “These guidelines will likely help neurosurgeons and neurologists to better select the surgical target for DBS surgery based on clinical features. It is our hope that the guidelines prove helpful for both treating physicians and patients with Parkinson’s disease.”
The guideline was developed by the CNS and has been endorsed by the Joint Guidelines Committee of Congress of Neurological Surgeons and the American Association of Neurological Surgeons.
About the Congress of Neurological Surgeons (CNS)
We are the leader in education and innovation, dedicated to advancing neurosurgery. We practice this by inspiring and facilitating scientific discovery and its translation to clinical practice for our members. The CNS provides members with the educational and career development opportunities they need to become leaders and innovators in the field.
Neurosurgery, the official journal of the Congress of Neurological Surgeons publishes research on clinical and experimental neurosurgery covering the very latest developments in science, technology, and medicine. Neurosurgery is the fastest-growing journal in the field, with a worldwide reputation for reliable coverage delivered with a fresh and dynamic outlook.